T. Rowe Price Associates’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,465,161
| Closed | -$105M | – | 2989 |
|
|
2023
Q4 | $105M | Buy |
4,465,161
+2,561,460
| +135% | +$60.5M | 0.01% | 533 |
|
|
2023
Q3 | $28.4M | Buy |
1,903,701
+1,809,280
| +1,916% | +$27M | ﹤0.01% | 829 |
|
|
2023
Q2 | $1.03M | Buy |
94,421
+21,810
| +30% | +$239K | ﹤0.01% | 1790 |
|
|
2023
Q1 | $634K | Sell |
72,611
-56,806
| -44% | -$496K | ﹤0.01% | 2005 |
|
|
2022
Q4 | $811K | Sell |
129,417
-45,683
| -26% | -$286K | ﹤0.01% | 1878 |
|
|
2022
Q3 | $613K | Buy |
175,100
+52,900
| +43% | +$185K | ﹤0.01% | 2019 |
|
|
2022
Q2 | $360K | Buy |
122,200
+12,077
| +11% | +$35.6K | ﹤0.01% | 2362 |
|
|
2022
Q1 | $342K | Buy |
110,123
+13,472
| +14% | +$41.8K | ﹤0.01% | 2493 |
|
|
2021
Q4 | $327K | Sell |
96,651
-40,923
| -30% | -$138K | ﹤0.01% | 2563 |
|
|
2021
Q3 | $502K | Hold |
137,574
| – | – | ﹤0.01% | 2380 |
|
|
2021
Q2 | $600K | Buy |
137,574
+68,239
| +98% | +$298K | ﹤0.01% | 2296 |
|
|
2021
Q1 | $315K | Buy |
69,335
+21,377
| +45% | +$97.1K | ﹤0.01% | 2546 |
|
|
2020
Q4 | $275K | Buy |
47,958
+24,400
| +104% | +$140K | ﹤0.01% | 2453 |
|
|
2020
Q3 | $171K | Buy |
+23,558
| New | +$171K | ﹤0.01% | 2447 |
|
|
2018
Q4 | – | Sell |
-410,967
| Closed | -$4.55M | – | 2590 |
|
|
2018
Q3 | $4.55M | Sell |
410,967
-276,310
| -40% | -$3.06M | ﹤0.01% | 1465 |
|
|
2018
Q2 | $9.22M | Sell |
687,277
-12,823
| -2% | -$172K | ﹤0.01% | 1358 |
|
|
2018
Q1 | $9.09M | Buy |
+700,100
| New | +$9.09M | ﹤0.01% | 1349 |
|